Nederlands
English
About VIB
Currently selected
Science communication
Home
>
About VIB
>
Press
Refine
Theme
About VIB (92)
Arabidopsis (3)
Bioinformatics (11)
Biotech basics (1)
Cancer (69)
Cardiovascular medicine (11)
Cell biology (9)
Grand Challenges (4)
Immunology (32)
Inflammation and immunity (55)
Microbiology (23)
Model Organisms (4)
Mouse (2)
Neuroscience (59)
Plant biology (41)
Proteomics (5)
Research Areas (3)
Science ethics (2)
Structural biology (17)
Systems biology (2)
Yeast (1)
Category
BioInformatics Training and Service facility (1)
Business opportunities (8)
Developmental biology (1)
Event (8)
News (34)
Research services (5)
Page Content Zone 1
Press
Receive VIB press releases
Email updates
Follow us on Twitter
Like us on Facebook
RSS
Contact
For all press inquiries, contact
Katrina Wright
Tel.: +32 9 244 66 11
Recent press releases
Peter Vandenabeele (VIB-UGent) receives FWO excellence prize
1 July 2015
Every five years, FWO Flanders selects five exceptional scientists in Flanders who play an international leading role in their field and have pushed the boundaries of their field.
Immunovaccine Initiates Clinical Trial with DPX-RSV Vaccine
30 June 2015
Immunovaccine Inc. announced that it has enrolled the first healthy adult volunteer in a Phase 1 clinical study of its respiratory syncytial virus (RSV) vaccine.
Oncurious NV Appoints Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor
26 June 2015
Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the appointment of Prof. Dr Peter Carmeliet as its Chief Scientific Strategy Advisor.
Circulating immune cells and cancer, novel insights might lead the way to optimizing diagnosis and treatment
25 June 2015
One of the things Max Mazzone (Vesalius Research Center) focuses on is the role of our immune system in cancer. And this has recently lead to two important breakthroughs published in Nature and Gut.
New biotech company Confo Therapeutics launched by VIB and Vrije Universiteit Brussel: Capricorn Venture Partners leads 1st financing round of € 3 million
24 June 2015
The establishment of Confo Therapeutics, a spin-off of VIB and Vrije Universiteit Brussel, was announced today. A consortium led by Capricorn Health-Tech Fund with the participation of Qbic and SOFI.
New insights could result in changes to the therapeutic strategy to combat Alzheimer’s
26 May 2015
Scientists at VIB, KU Leuven and Janssen Pharmaceutica have demonstrated that the distribution of aggregates through the brain is facilitated by synaptic connections between brain cells.
VIB and Performa Investimentos establish GlobalYeast to deliver superior industrial yeast strains for the bio based economy
21 May 2015
VIB and Performa Investimentos today announced the establishment of GlobalYeast, a new company that will develop and deliver superior industrial yeast strains for bioethanol and the green chemicals industry.
Tara Oceans expedition sheds light on the world of plankton
21 May 2015
Plankton is our most important source of oxygen.
How risky is working at VIB
18 May 2015
Overview of accidents at VIB.
Novel insights in MET-proto-oncogene might lead to optimizing cancer treatment
18 May 2015
The MET-proto-oncogene is involved in the pathogenesis of several tumors and therefore represents an interesting target for future therapies currently tested in dozens of clinical trials.
A step forward in understanding muscle diseases
4 May 2015
Rouslan Efremov, together with his former colleagues from Max Planck, unraveled the structure and mechanism of the ryanodine receptor.
Quickscan scientific publications 1st quarter 2015
27 April 2015
VIB's scientific publications 1st quarter 2015
The genome sequence of the orchid Phalaenopsis equestris
20 April 2015
The lab of Yves Van de Peer (VIB Department of Plant Systems Biology) can add an extra genome paper to its long list.
Cell sorting at VIB
16 April 2015
Cell sorting technology enables rapid separation of large numbers of specific cell populations with high purity, recovery, and yield, starting from single cell suspensions.
ThromboGenics and VIB launch New Oncology Company Oncurious NV to develop TB-403 for Pediatric Brain Tumours
14 April 2015
ThromboGenics NV announces the foundation of Oncurious NV, a new oncology company that will develop TB-403 for the treatment of pediatric brain tumors. VIB will become a shareholder alongside ThromboGenics in this new oncology venture.
«Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Next»
Page Content Zone 2
Page Content Zone 3